Trousdale M D, Goldschmidt P L, Nóbrega R
Doheny Eye Institute, Los Angeles, California 90033.
Cornea. 1994 Sep;13(5):435-9. doi: 10.1097/00003226-199409000-00011.
The most common causes of acute viral infections of the eye for which there are no effective antiviral drugs are the adenoviruses. Until recently, pathogenesis studies and antiviral drug testing for adenovirus-induced ocular disease were not practical because no animal model was available. However, new animal models for human adenovirus-induced ocular and respiratory infections have now made such studies possible. We assessed the in vitro and in vivo activity of ganciclovir against a genetically defined adenovirus (Ad5 wt 300) known to cause severe ocular disease. The 50% inhibitory dose (ID50) values were determined by plaque reduction assays in human cells. The ID50 values of 47 and 604 microM were determined for ganciclovir and acyclovir, respectively, against Ad5, and 26 and 152 microM, respectively against Ad8. Cotton rats were inoculated bilaterally with 10(5) plaque-forming units per eye and treated topically with ganciclovir (3%, 1%, or 0.3%) or placebo for 21 days. All inoculated eyes were culture positive on days 1-3 with increased infectivity titers, regardless of treatment. However, the incidence, duration, and titer of virus shed in eyes treated with 3% ganciclovir was reduced, and the antiadenovirus enzyme-linked immunosorbent assay titers in serum were lower in these animals. Although these differences were not statistically significant, the observed trend suggested that the highest ganciclovir dose had a suppressive effect on some disease parameters.
尚无有效抗病毒药物的眼部急性病毒感染最常见的病因是腺病毒。直到最近,由于没有可用的动物模型,腺病毒所致眼病的发病机制研究和抗病毒药物测试都不切实际。然而,现在人类腺病毒所致眼部和呼吸道感染的新动物模型使此类研究成为可能。我们评估了更昔洛韦对一种已知会引起严重眼病的基因明确的腺病毒(Ad5 wt 300)的体外和体内活性。通过在人细胞中进行蚀斑减少试验来确定50%抑制剂量(ID50)值。更昔洛韦和阿昔洛韦针对Ad5的ID50值分别确定为47和604微摩尔,针对Ad8的ID50值分别为26和152微摩尔。给棉鼠每只眼双侧接种10⁵蚀斑形成单位,并局部用更昔洛韦(3%、1%或0.3%)或安慰剂治疗21天。无论治疗如何,所有接种的眼睛在第1至3天培养均为阳性,且感染性滴度增加。然而,用3%更昔洛韦治疗的眼睛中病毒排出的发生率、持续时间和滴度降低,并且这些动物血清中的抗腺病毒酶联免疫吸附试验滴度较低。尽管这些差异无统计学意义,但观察到的趋势表明最高剂量的更昔洛韦对某些疾病参数有抑制作用。